Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the long-term data from a Phase I study (NCT03005782) of fianlimab and cemiplimab, noting that patients with a partial response or better tend to have a favorable outcome. If progression does not occur within a certain timeframe, approximately three years, the likelihood of never progressing is 95% or higher, allowing for a positive prognosis for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.